Roche Partners With COUR in Autoimmune Deal Potentially Worth More Than $900M

The collaboration will see COUR and Roche’s Genentech leverage the biotech’s antigen-specific immune tolerance platform to develop and commercialize therapies for an undisclosed autoimmune disease.